Extended use of temozolomide for glioma patients based on MGMT expression pattern: experience of 32 cases

Gang Li,Qun-ying Yang,Ying Guo,Yong-gao Mou,Xiang-heng Zhang,Qiu-liang Wu,Shi-ming He,Liang Wang,Bao-fu Li,Fu-qiang Feng,Pei-gang Ji,Guo-dong Gao,Zhong-ping Chen

2012-01-01

Abstract:BACKGROUND & OBJECTIVE: The 6-cycle regimen of temozolomide(TMZ) has been used for gliomas as a standard chemotherapy.This article is to review our experience of 32 patients with high-grade gliomas(HGGs) and low-grade gliomas(LGGs) with extend TMZ chemotherapy(more than 6 cycles).METHODS: The regimen of TMZ chemotherapy was selected based on MGMT expression of the tumor.Additionally,MGMT promoter methylation status is performed in 6 patients of them.Patients with MGMT-negative tumors(± or-) had received the standard dosing regimen(200 mg/m2 for 5 days every 28 days).While patients with MGMT-positive tumors(++ or +) were treated with TMZ(75 mg/m2 Day 1-21)using the 3-weeks-on/1-week-off(21 of 28 days) schedule,or the adjusted regimen of cisplatin plus TMZ(cisplatin 75 mg/m2 on Day 1 and 2,TMZ 200 mg/m2 on Day 2 to 6,every 28 days).RESULTS: About 318 cycles of TMZ were administered to the 32 patients.The number of TMZ cycles administered per patient ranged from 7 to 24(median = 9.4 cycles).Myelosuppression including lymphopenia and leukopenia were the most common high grade toxicities(grade 3),both occurring in 9.4 %(3 / 32) of patients.The most frequent toxicities were fatigue(86.9 %),neutro penia(46.9 %),alopecia(46.9 %),and so on.The median progress free survival(PFS) was 28.6 months.Six month PFS and 12 month PFS were 100% and 71% respectively.And 15 out of the 32 patients received gross total resection,showing no evidence of disease.According to intention-to-treat principle,one patient(3.1 %) demonstrated a complete response(CR),14 patients(43.8 %) demonstrated a minor response(MR),and two patients(6.2 %) demonstrated stable disease(SD);the overall response rate(ORR) was 81.5 %(95% CI,50%-96%) and the disease control rate(DCR) was 89.2%(95% CI,64%-98%).CONCLUSION: Extended use of TMZ based on MGMT expression pattern is safe to patients with gliomas,which may improve response rates and PFSs compared to conventional regimen.